Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors in HER2-positive Advanced Biliary Tract Cancer
NCT07159217Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2025
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in biliary tract cancer (BTC), sponsored by Peking Union Medical College Hospital. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07159217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07159217.